JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competiti

Four Dividend Kings with streaks stretching back decades sit inside millions of retirement portfolio

New Johnson and Johnson ICOTYDEÂ (icotrokinra) long-term data demonstrate robust 2-year results in t

ICOTYDE clinical data highlights2High levels of skin clearance were observed at Week 112, with ≥72%

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults an

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthen

A $500,000 portfolio of high-yield REITs and BDCs can quietly hand five figures every year straight

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the righ

A fat yield can vanish overnight, but four dividend stocks on this list show you exactly where the c

Three sectors are higher and eight are lower in Thursday's regular session, with the top three s

Besides Wall Street's top-and-bottom-line estimates for Johnson & Johnson (JNJ), review projections

Johnson & Johnson's decision to separate from its consumer health segment could help raise top-line

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quar

Procter and Gamble has raised its dividend every year for seven decades, and it is not even the high

Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risk

Two of 11 sectors are higher in Wednesday's regular session, with defensive sectors holding the

Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a M

Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintai

Market indicators are flashing red heading into October, and investors who wait too long to repositi

Fortress Biotech (NASDAQ: FBIO - Get Free Report) and Johnson and Johnson (NYSE: JNJ - Get Free Repo

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson and Johnson (NYSE:

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of PPG Industries, Inc. (NYSE

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of The Home Depot, Inc. (NYSE

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of International Business Mac

Dave Ramsey and Suze Orman have built careers on helping people retire with dignity, yet on one of t

J&J's MedTech faces Abiomed and competitive pressures, but Vision, Orthopedics and Surgery could dri

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard

Yield alone tells you nothing about whether a dividend actually survives a recession or a patent cli

Nine of 11 sectors are higher in Tuesday’s regular session, with defensive sectors holding two of th

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likel

RBC Capital analyst Trung Huynh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and

Both Dividend Kings trade at nearly identical valuations, so the real question becomes which one can

Johnson & Johnson (JNJ) closed at $252.83 in the latest trading session, marking a -1.25% move from

Rockland Trust Co. reduced its position in Johnson and Johnson (NYSE: JNJ) by 5.3% during the undefi

Ferguson Wellman Capital Management Inc. increased its holdings in Johnson and Johnson (NYSE: JNJ) b

Eastern Bank increased its stake in Johnson and Johnson (NYSE: JNJ) by 105.9% in the undefined quart

Park National Corp OH lowered its position in Johnson and Johnson (NYSE: JNJ) by 4.8% in the undefin

Argent Capital Management LLC decreased its holdings in Johnson and Johnson (NYSE: JNJ) by 5.5% in t

J&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's che

Eight sectors are higher and three are lower in Monday's regular session, with growth, cyclical

These companies haven't said their last words.

Even in a recession, there's strong demand for J&J's myriad of pharmaceutical and healthcare product

MassMutual Private Wealth and Trust FSB lessened its holdings in shares of Johnson and Johnson (NYSE

Violich Capital Management Inc. cut its stake in Johnson and Johnson (NYSE: JNJ) by 5.0% during the

Your tax bracket quietly decides whether muni bonds or dividend stocks put more cash in your pocket,

Friday's regular session has eight sectors higher and three lower, with growth sectors holding t

The late-breaking results, shared as an oral presentation at the European Academy of Dermatology and

Johnson & Johnson reports Q3 earnings Oct. 13; EPS seen at $2.48, revenue $25.31B. Analysts are

Analysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below conse

JP Morgan analyst Chris Schott maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and rais